Impact of etanercept tapering on work productivity in patients with early rheumatoid arthritis: results from the PRIZE study.

ABSTRACT:

Objective

To assess changes in work productivity in patients who have achieved response using etanercept (ETN) 50 mg+methotrexate (MTX) (phase I) are randomised to ETN 25 mg+MTX versus MTX versus placebo (phase II) and then withdrawn from treatment (phase III).

Methods

Patients included in the analysis were in employment entering phase II of the PRIZE trial and had one or more follow-ups. Phase II was a 39-week, randomised and double-blind comparison of the 3 dose-reduction treatments. Phase III was a 26-week observational study where treatment was withdrawn. The Valuation of Lost Productivity was completed approximately every 13 weeks to estimate productivity impacts from a societal perspective.

Results

A total of 120 participants were included in our analyses. Durin

SUBMITTER: Zhang W 

PROVIDER: S-EPMC4947791 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature